Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT1 | P04628 | 13/20 | 0.70 |
| ▸ | TGFBR1 | P36897 | 11/20 | 0.70 |
| ▸ | CLK2 | P49760 | 8/20 | 0.65 |
| ▸ | CLK3 | P49761 | 8/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15370972 | 0.94 | WNT1 (0.68) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL12370796 | 0.94 | WNT1 (0.69) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL12370227 | 0.94 | WNT1 (0.68) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL15370977 | 0.93 | WNT1 (0.68) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL2270471 | 0.93 | CLK2 (0.73) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL15617350 | 0.92 | WNT1 (0.68) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL12370263 | 0.92 | WNT1 (0.80) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL12370243 | 0.92 | CLK2 (0.73) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL12370200 | 0.92 | WNT1 (0.68) | WNT1TGFBR1CLK2CLK3DYRK1A | |
| SCHEMBL15370981 | 0.92 | WNT1 (0.67) | WNT1TGFBR1CLK2CLK3DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200155525-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC | 2020-05-21 | — | — | US | disclosed |
| US-10342788-B2 | 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190134013-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2019-05-09 | — | — | US | disclosed |
| US-20180141963-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2018-05-24 | — | — | US | disclosed |
| EP-3305073-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | Samumed, LLC (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9855272-B2 | 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170333409-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2017-11-23 | — | — | US | disclosed |
| US-20170333409-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2017-11-23 | — | — | US | disclosed |
| EP-3001903-B1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED LLC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9758531-B2 | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-09-12 | — | — | US | disclosed |
| WO-2013166396-A2 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-11-07 | — | — | WO | disclosed |
| US-20130296302-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296307-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2013-11-07 | — | — | US | disclosed |
| US-20130225576-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225576-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-08-29 | — | — | US | disclosed |
| US-8450340-B2 | 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450340-B2 | 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110190290-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190290-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2011084486-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333409-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | COL1A1, NOX4, FGF1 | WNT1 41/4885TGFBR1 135/4885CLK2 1922/4885 |
| US-20110190290-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | BRCA1, THPO, PDXK | WNT1 766/4885TGFBR1 3681/4885CLK2 2380/4885 |
| US-20130225576-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | BRCA1, THPO, PDXK | WNT1 766/4885TGFBR1 3681/4885CLK2 2380/4885 |
| US-20190134013-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | COL1A1, NOX4, FGF1 | WNT1 41/4885TGFBR1 135/4885CLK2 1922/4885 |
| US-10342788-B2 | 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | COL1A1, NOX4, FGF1 | WNT1 41/4885TGFBR1 135/4885CLK2 1922/4885 |
| US-20130296302-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | COL1A1, NOX4, FGF1 | WNT1 41/4885TGFBR1 135/4885CLK2 1922/4885 |
| US-20180141963-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | WNT1 1/4885TGFBR1 339/4885CLK2 2494/4885 |
| US-20130296307-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | BRCA1, THPO, PDXK | WNT1 766/4885TGFBR1 3681/4885CLK2 2380/4885 |
| US-20200155525-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | COL1A1, NOX4, FGF1 | WNT1 41/4885TGFBR1 135/4885CLK2 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.